 "Stada receives takeover bids from Cinven & Advent International")
Stada Arzneimittel AG, the German manufacturer of generic and OTC (over-the-counter) drugs, has confirmed that it has received two legally non-binding expressions of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company.
One of the proposal was submitted by private equity group Cinven Partners LLP at an indicative takeover price of Euro 56.00 per Stada share – the cumulative value of which amounts to € 3.5 billion. Stada received the second proposal from Advent International Corporation.
“Both legally non-binding expressions of interest from Cinven Partners LLP and from Advent International Corporation, which the executive board considered for some time, could offer in different ways attractive opportunities in the interest of the company. The executive board has therefore started open-minded talks to allow the interested parties to explain their strategic concepts and evaluate further value-enhancing potential with regards to the potential offer price,” said Stada in a press statement.
Stada Arzneimittel consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The group is the only independent generics producer in Germany. Worldwide, Stada is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2015, Stada achieved Group sales of € 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of € 389.4 million and adjusted net income of € 165.8 million.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%